Perflubutane - Daiichi Sankyo/GE Healthcare

Drug Profile

Perflubutane - Daiichi Sankyo/GE Healthcare

Alternative Names: DD-723; DD-723-B; NC-100100; NUS; Sonazoid

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GE Healthcare
  • Developer Daiichi Sankyo Company; GE Healthcare; Yonsei University Health System
  • Class Contrast media; Fluorocarbons; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Liver cancer
  • Phase III Hepatocellular carcinoma
  • Discontinued Prostate cancer; Vascular disorders

Most Recent Events

  • 10 Aug 2012 Registered for Breast cancer in Japan (IV)
  • 31 Jan 2012 Preregistration for Breast cancer diagnosis in Japan (IV)
  • 29 Jan 2010 Phase-II clinical trials in Breast cancer diagnosis in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top